Dec 2, 2019   SOURCE: PR NewsWire

Ionis Pharmaceuticals to hold technology webcast

CARLSBAD, Calif., Dec. 2, 2019 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Friday, December 13(th) at 11:00 a.m. Eastern Time to take a deep dive into antisense technology, Ionis' proprietary RNA-targeted drug discovery platform. The approximately two-hour webcast will include presentations from Ionis' key architects and pioneers of RNA-targeted therapeutics Stanley T. Crook, MD, PhD, chief executive officer and chairman; Brett P. Monia, PhD, chief operating officer; Frank C. Bennett, PhD, senior vice president, research and neurology, and Eric Swayze, PhD, vice president, chemistry. The agenda for the webcast will be as follows:

        
            
              Topic               Presenter

                   ---


       Introduction                       
      
        Stan

    ---


       Optimization of Antisense          
      
        Eric

    ---

        Enhancing Productive Delivery in
         vivo (LICA)                      
      
        Frank

    ---

        New Routes of Local Delivery      
      
        Frank

    ---

        Commercially Attractive Oral
         Delivery                         
      
        Brett

    ---

        Bridging the Gap Between the Gene
         and the Patient                  
      
        Brett

    ---

        New Advances in Core Antisense
         Research                          
      
        Stan

    ---


       Conclusions                        
      
        Stan

    ---


       Q&A                                
      
        All

    ---

Interested parties may access the webcast here. A webcast replay will be available for a limited time at the same address.

About Ionis Pharmaceuticals
As the leader in RNA-targeted drug discovery and development, Ionis has created an efficient, broadly applicable, drug discovery platform called antisense technology that can treat diseases where no other therapeutic approaches have proven effective. Our drug discovery platform has served as a springboard for actionable promise and realized hope for patients with unmet needs. We created the first and only approved treatment for children and adults with spinal muscular atrophy as well as the world's first RNA-targeted therapeutic approved for the treatment of polyneuropathy in adults with hereditary transthyretin amyloidosis. Our sights are set on all the patients we have yet to reach with a pipeline of more than 40 novel medicines designed to treat a broad range of diseases including cardiovascular diseases, neurological diseases, infectious diseases, pulmonary diseases and cancer.

To learn more about Ionis visit www.ionispharma.com and follow us on twitter @ionispharma.

View original content to download multimedia:http://www.prnewswire.com/news-releases/ionis-pharmaceuticals-to-hold-technology-webcast-300965854.html

SOURCE Ionis Pharmaceuticals, Inc.